Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INF-101
- Development stage
- Preclinical
- Lead developer
- Inflamalps
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
INF-101 (also known as INF101) is a preclinical-stage small molecule peptide hydrolase (protease) inhibitor originally developed by OncoNOx and subsequently in-licensed by Inflamalps for the topical treatment of chronic inflammatory eye diseases. The drug is designed to inhibit peptide hydrolase (peptidases), which blocks the production of inflammatory cytokines involved in dry eye syndrome. In preclinical animal models of dry eye, topical administration of INF-101 demonstrated anti-inflammatory efficacy comparable to cyclosporine A. Inflamalps is developing INF-101 for the treatment of dry eye syndromes (including dry eye associated with Sjögren's syndrome) and uveitis.
Beyond the preview
Go deeper on INF-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INF-101.